United States Women Health Laboratory Testing Market By Hereditary Cancer (Cervical Cancer, Ovarian Cancer, Breast Cancer), By Reproductive Health and Infectious Diseases (CT/NG Testing, Preimplantation Genetic Testing (PGT), Herpes Simplex Virus (HSV), Hepatitis, Sexually Transmitted Infections, Vaginal Infections, PAP Smear Testing, HIV Testing, Pregnancy and Ovulation Testing, HPV Testing), By Prenatal Screening and Diagnostic Testing (Non-Invasive Prenatal Testing (NIPT), Maternal Serum Screening (MSS), Prenatal Diagnostic Testing), By Region, Competition Forecast & Opportunities, 2018-2028
United States Women Health Laboratory Testing Market is expected to grow at an impressive rate during the forecast period, 2024-2028. The major factors include the increasing prevalence of chronic diseases, trauma, anemia, myeloma, lymphoma, leukemia, etc., rising awareness regarding women's health-related tests, rising cases of aneuploidies, and medical advancement. The rising prevalence of cancer among the women population has significantly created new prospects for the growth of the United States Women Health Laboratory Testing Market. According to Global Cancer Observatory, in 2020, around 1 0,55,117 new cancer cases were reported in the United States.
Additionally, the other factor includes the increasing investments in the healthcare sector, the major involvement of market players, and the increase in the number of funding activities. Various initiatives and awareness programs are taken by government or private organizations to raise awareness about diseases and treatments, as well as information about the availability of more advanced technologies and procedures at healthcare facilities.
Prevalence of Chronic diseases
The prevalence of chronic diseases like cardiovascular diseases, surgeries, trauma, and injuries either caused due to road accidents or any other accidental or non-accidental reasons are resulting in the growth of the market. The main cause of the increasing demand for laboratory testing procedures is increased health issues in women and the demand for the treatment of various severe diseases like cancer. According to the American Cancer Society, more than 1.8 million people were diagnosed with cancer in 2020. For instance, an estimated 1,519,907 people in the United States are suffering from leukemia, lymphoma, myeloma, myelodysplastic syndromes (MDS), or myeloproliferative neoplasms (MPNs). Additionally, in terms of health, women health varies from men in distinctive ways. Therefore, timely diagnosis/testing of a disease is important for getting management and treatment for the disease. Also, the significant increase in the prevalence of cancer and certain infectious diseases, such as sexually transmitted diseases, immunodeficiency virus (HIV), Hepatitis, Syphilis, etc., is driving the growth of the women health laboratory testing market in the United States.
Recent Developments
In November 2022, a new molecular diagnostic company, namely Roche Holdings, launched Cobas 5800 to expand access to PCR testing in the United States. The whole system unit assists in the diagnosis of infectious diseases such as HIV, human papillomavirus, syphilis, sexually transmitted diseases, etc. Additionally, in October 2019, Myriad Genetics, Inc. announced that the U.S. Food and Drug Administration (FDA) approved myChoice CDx for use as a companion diagnostic for Treatment with Zejula in late-line ovarian cancer.
Growing awareness amongst key players in the market
Several market players are getting aware of women health and diseases. Therefore, they are participating in the development of diagnostic procedures for the impressive growth of the market. Also, certain mergers and acquisitions lead to the steady growth of the market. For instance, in February 2022, Laboratory Corporation of America Holdings established a strategic partnership with Ascension to expand its testing capabilities. Additionally, in January 2022, a company, namely Your Gene Health, announced that it had signed a strategic partnership agreement with a point-of-care business, namely EKF Diagnostics Holdings plc, with accredited laboratory testing capabilities in the U.S.
Market Segmentation
United States Women Health Laboratory Testing Market can be segmented into hereditary cancer, reproductive health, and infectious diseases, prenatal screening and diagnostic testing, region, and competitive landscape. By hereditary cancer, the market can be segmented into Cervical Cancer, Ovarian Cancer, and Breast Cancer. Based on reproductive health and infectious diseases, the market can be split into CT/NG Testing, Preimplantation Genetic Testing (PGT), Herpes Simplex Virus (HSV), Hepatitis, Sexually Transmitted Infections, Vaginal Infections, PAP Smear Testing, HIV Testing, Pregnancy and Ovulation Testing, HPV Testing. In terms of prenatal screening and diagnostic testing, the market can be segmented into Non-Invasive Prenatal Testing (NIPT), Maternal Serum Screening (MSS), and Prenatal Diagnostic Testing.
Market Players
F. Hoffmann-La Roche AG., Stanbio Laboratory L.P., Yourgene Health, Myriad Genetics Inc., Natera, Inc., Ovia Health, Laboratory Corporation of America Holdings, Inc., Gateway Genomics, LLC, Ascension Healthcare Network Inc, EKF Diagnostics Holdings Plc, etc. are some of the leading companies operating in the market.
Report Scope:
In this report, United States Women Health Laboratory Testing Market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in United States Women Health Laboratory Testing Market
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
Additionally, the other factor includes the increasing investments in the healthcare sector, the major involvement of market players, and the increase in the number of funding activities. Various initiatives and awareness programs are taken by government or private organizations to raise awareness about diseases and treatments, as well as information about the availability of more advanced technologies and procedures at healthcare facilities.
Prevalence of Chronic diseases
The prevalence of chronic diseases like cardiovascular diseases, surgeries, trauma, and injuries either caused due to road accidents or any other accidental or non-accidental reasons are resulting in the growth of the market. The main cause of the increasing demand for laboratory testing procedures is increased health issues in women and the demand for the treatment of various severe diseases like cancer. According to the American Cancer Society, more than 1.8 million people were diagnosed with cancer in 2020. For instance, an estimated 1,519,907 people in the United States are suffering from leukemia, lymphoma, myeloma, myelodysplastic syndromes (MDS), or myeloproliferative neoplasms (MPNs). Additionally, in terms of health, women health varies from men in distinctive ways. Therefore, timely diagnosis/testing of a disease is important for getting management and treatment for the disease. Also, the significant increase in the prevalence of cancer and certain infectious diseases, such as sexually transmitted diseases, immunodeficiency virus (HIV), Hepatitis, Syphilis, etc., is driving the growth of the women health laboratory testing market in the United States.
Recent Developments
In November 2022, a new molecular diagnostic company, namely Roche Holdings, launched Cobas 5800 to expand access to PCR testing in the United States. The whole system unit assists in the diagnosis of infectious diseases such as HIV, human papillomavirus, syphilis, sexually transmitted diseases, etc. Additionally, in October 2019, Myriad Genetics, Inc. announced that the U.S. Food and Drug Administration (FDA) approved myChoice CDx for use as a companion diagnostic for Treatment with Zejula in late-line ovarian cancer.
Growing awareness amongst key players in the market
Several market players are getting aware of women health and diseases. Therefore, they are participating in the development of diagnostic procedures for the impressive growth of the market. Also, certain mergers and acquisitions lead to the steady growth of the market. For instance, in February 2022, Laboratory Corporation of America Holdings established a strategic partnership with Ascension to expand its testing capabilities. Additionally, in January 2022, a company, namely Your Gene Health, announced that it had signed a strategic partnership agreement with a point-of-care business, namely EKF Diagnostics Holdings plc, with accredited laboratory testing capabilities in the U.S.
Market Segmentation
United States Women Health Laboratory Testing Market can be segmented into hereditary cancer, reproductive health, and infectious diseases, prenatal screening and diagnostic testing, region, and competitive landscape. By hereditary cancer, the market can be segmented into Cervical Cancer, Ovarian Cancer, and Breast Cancer. Based on reproductive health and infectious diseases, the market can be split into CT/NG Testing, Preimplantation Genetic Testing (PGT), Herpes Simplex Virus (HSV), Hepatitis, Sexually Transmitted Infections, Vaginal Infections, PAP Smear Testing, HIV Testing, Pregnancy and Ovulation Testing, HPV Testing. In terms of prenatal screening and diagnostic testing, the market can be segmented into Non-Invasive Prenatal Testing (NIPT), Maternal Serum Screening (MSS), and Prenatal Diagnostic Testing.
Market Players
F. Hoffmann-La Roche AG., Stanbio Laboratory L.P., Yourgene Health, Myriad Genetics Inc., Natera, Inc., Ovia Health, Laboratory Corporation of America Holdings, Inc., Gateway Genomics, LLC, Ascension Healthcare Network Inc, EKF Diagnostics Holdings Plc, etc. are some of the leading companies operating in the market.
Report Scope:
In this report, United States Women Health Laboratory Testing Market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:
- United States Women Health Laboratory Testing Market, By Hereditary Cancer
- Cervical Cancer
- Ovarian Cancer
- Breast Cancer
- United States Women Health Laboratory Testing Market, By Reproductive Health and Infectious Diseases
- CT/NG Testing,
- Preimplantation Genetic Testing (PGT)
- Herpes Simplex Virus (HSV)
- Hepatitis
- Sexually Transmitted Infections
- Vaginal Infections
- PAP Smear Testing
- HIV Testing
- Pregnancy and Ovulation Testing
- HPV Testing
- United States Women Health Laboratory Testing Market, By Prenatal Screening and Diagnostic Testing
- Non-Invasive Prenatal Testing (NIPT)
- Maternal Serum Screening (MSS)
- Prenatal Diagnostic Testing
- United States Women Health Laboratory Testing Market, By Region:
- Northeast
- Midwest
- South
- West
Company Profiles: Detailed analysis of the major companies present in United States Women Health Laboratory Testing Market
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. UNITED STATES WOMEN HEALTH LABORATORY TESTING MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Hereditary Cancer (Cervical Cancer, Ovarian Cancer, Breast Cancer)
5.2.2. By Reproductive Health and Infectious Diseases (CT/NG Testing, Preimplantation Genetic Testing (PGT), Herpes Simplex Virus (HSV), Hepatitis, Sexually Transmitted Infections, Vaginal Infections, PAP Smear Testing, HIV Testing, Pregnancy and Ovulation Testing, HPV Testing)
5.2.3. By Prenatal Screening and Diagnostic Testing (Non-Invasive Prenatal Testing (NIPT), Maternal Serum Screening (MSS), Prenatal Diagnostic Testing)
5.2.4. By Region (Northeast Region, Midwest Region, South Region, West Region)
5.2.5. By Company (2022)
5.3. Market Map
5.3.1. By Hereditary Cancer
5.3.2. By Reproductive Health and Infectious Diseases
5.3.3. By Prenatal Screening and Diagnostic Testing
5.3.4. By Region
6. NORTHEAST UNITED STATES WOMEN HEALTH LABORATORY TESTING MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Hereditary Cancer
6.2.2. By Reproductive Health and Infectious Diseases
6.2.3. By Prenatal Screening and Diagnostic Testing
7. MIDWEST UNITED STATES WOMEN HEALTH LABORATORY TESTING MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Hereditary Cancer
7.2.2. By Reproductive Health and Infectious Diseases
7.2.3. By Prenatal Screening and Diagnostic Testing
8. SOUTH UNITED STATES WOMEN HEALTH LABORATORY TESTING MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Hereditary Cancer
8.2.2. By Reproductive Health and Infectious Diseases
8.2.3. By Prenatal Screening and Diagnostic Testing
9. WEST UNITED STATES WOMEN HEALTH LABORATORY TESTING MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Hereditary Cancer
9.2.2. By Reproductive Health and Infectious Diseases
9.2.3. By Prenatal Screening and Diagnostic Testing
10. MARKET DYNAMICS
10.1. Drivers
10.1.1. Prevalence of Chronic diseases
10.1.2. Recent Developments
10.1.3. Growing awareness amongst key players of the market
10.2. Challenges
10.2.1. Stringent Regulatory Guidelines Related to Laboratory Testing
10.2.2. Disparity in Awareness of Pregnancy and Fertility Issues in the Different Regions of the United States
11. MARKET TRENDS & DEVELOPMENTS
12. UNITED STATES ECONOMIC PROFILE
13. COMPETITIVE LANDSCAPE
13.1. Business Overview
13.2. Product Offerings
13.3. Recent Developments
13.4. Financials (In Case of Listed Companies)
13.5. Key Personnel
13.5.1. F. Hoffmann-La Roche AG.
13.5.2. Stanbio Laboratory L.P.
13.5.3. Yourgene Health
13.5.4. Myriad Genetics Inc.
13.5.5. Natera, Inc.
13.5.6. Ovia Health
13.5.7. Laboratory Corporation of America Holdings, Inc.
13.5.8. Gateway Genomics, LLC
13.5.9. Ascension Healthcare Network Inc
13.5.10. EKF Diagnostics Holdings Plc
14. STRATEGIC RECOMMENDATIONS
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. UNITED STATES WOMEN HEALTH LABORATORY TESTING MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Hereditary Cancer (Cervical Cancer, Ovarian Cancer, Breast Cancer)
5.2.2. By Reproductive Health and Infectious Diseases (CT/NG Testing, Preimplantation Genetic Testing (PGT), Herpes Simplex Virus (HSV), Hepatitis, Sexually Transmitted Infections, Vaginal Infections, PAP Smear Testing, HIV Testing, Pregnancy and Ovulation Testing, HPV Testing)
5.2.3. By Prenatal Screening and Diagnostic Testing (Non-Invasive Prenatal Testing (NIPT), Maternal Serum Screening (MSS), Prenatal Diagnostic Testing)
5.2.4. By Region (Northeast Region, Midwest Region, South Region, West Region)
5.2.5. By Company (2022)
5.3. Market Map
5.3.1. By Hereditary Cancer
5.3.2. By Reproductive Health and Infectious Diseases
5.3.3. By Prenatal Screening and Diagnostic Testing
5.3.4. By Region
6. NORTHEAST UNITED STATES WOMEN HEALTH LABORATORY TESTING MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Hereditary Cancer
6.2.2. By Reproductive Health and Infectious Diseases
6.2.3. By Prenatal Screening and Diagnostic Testing
7. MIDWEST UNITED STATES WOMEN HEALTH LABORATORY TESTING MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Hereditary Cancer
7.2.2. By Reproductive Health and Infectious Diseases
7.2.3. By Prenatal Screening and Diagnostic Testing
8. SOUTH UNITED STATES WOMEN HEALTH LABORATORY TESTING MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Hereditary Cancer
8.2.2. By Reproductive Health and Infectious Diseases
8.2.3. By Prenatal Screening and Diagnostic Testing
9. WEST UNITED STATES WOMEN HEALTH LABORATORY TESTING MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Hereditary Cancer
9.2.2. By Reproductive Health and Infectious Diseases
9.2.3. By Prenatal Screening and Diagnostic Testing
10. MARKET DYNAMICS
10.1. Drivers
10.1.1. Prevalence of Chronic diseases
10.1.2. Recent Developments
10.1.3. Growing awareness amongst key players of the market
10.2. Challenges
10.2.1. Stringent Regulatory Guidelines Related to Laboratory Testing
10.2.2. Disparity in Awareness of Pregnancy and Fertility Issues in the Different Regions of the United States
11. MARKET TRENDS & DEVELOPMENTS
12. UNITED STATES ECONOMIC PROFILE
13. COMPETITIVE LANDSCAPE
13.1. Business Overview
13.2. Product Offerings
13.3. Recent Developments
13.4. Financials (In Case of Listed Companies)
13.5. Key Personnel
13.5.1. F. Hoffmann-La Roche AG.
13.5.2. Stanbio Laboratory L.P.
13.5.3. Yourgene Health
13.5.4. Myriad Genetics Inc.
13.5.5. Natera, Inc.
13.5.6. Ovia Health
13.5.7. Laboratory Corporation of America Holdings, Inc.
13.5.8. Gateway Genomics, LLC
13.5.9. Ascension Healthcare Network Inc
13.5.10. EKF Diagnostics Holdings Plc
14. STRATEGIC RECOMMENDATIONS
